Quarterly report pursuant to Section 13 or 15(d)

2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.19.1
2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jan. 31, 2019
Oct. 31, 2018
Jul. 31, 2018
Jan. 31, 2018
Oct. 31, 2017
Jul. 31, 2017
Jan. 31, 2019
Jan. 31, 2018
Apr. 30, 2018
Property, Plant and Equipment [Line Items]                  
Intangible assets $ 3,549,427           $ 3,549,427   $ 3,549,427
Impairment of intangible assets             0 $ 0  
Impairment of long-lived assets             $ 0 0  
U.S. federal income tax rate             21.00%    
Research and development costs 59,144     $ 802,564     $ 442,039 1,745,692  
Uninsured cash balances 307,000           307,000   772,000
Accumulated deficit (98,892,427)           (98,892,427)   $ (95,964,143)
Net loss $ (676,347) $ (1,036,574) $ (1,215,363) $ (2,030,660) $ (1,814,298) $ (1,688,415) $ (2,928,284) $ (5,533,373)  
SG Austria [Member]                  
Property, Plant and Equipment [Line Items]                  
Percentage investment in SG Austria 14.50%           14.50%    
Cell-in-a-Box [Member]                  
Property, Plant and Equipment [Line Items]                  
Intangible assets $ 1,549,427           $ 1,549,427    
Diabetes License [Member]                  
Property, Plant and Equipment [Line Items]                  
Intangible assets $ 2,000,000           $ 2,000,000